Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to Buy at StockNews.com

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was downgraded by research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Wednesday.

Aurinia Pharmaceuticals Stock Down 0.5 %

AUPH stock opened at $7.83 on Wednesday. The company has a 50 day moving average price of $8.33 and a two-hundred day moving average price of $7.68. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The stock has a market capitalization of $1.12 billion, a P/E ratio of -52.20 and a beta of 1.22. Aurinia Pharmaceuticals has a one year low of $4.71 and a one year high of $10.67.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in AUPH. CWM LLC grew its holdings in Aurinia Pharmaceuticals by 247.7% in the 3rd quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock valued at $84,000 after buying an additional 8,180 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Aurinia Pharmaceuticals by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock worth $202,000 after acquiring an additional 10,700 shares during the last quarter. Segall Bryant & Hamill LLC grew its holdings in Aurinia Pharmaceuticals by 1.6% in the third quarter. Segall Bryant & Hamill LLC now owns 562,775 shares of the biotechnology company’s stock valued at $4,125,000 after purchasing an additional 9,031 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Aurinia Pharmaceuticals during the third quarter worth approximately $3,330,000. Finally, Intech Investment Management LLC purchased a new position in Aurinia Pharmaceuticals during the third quarter worth approximately $262,000. 36.83% of the stock is currently owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.